Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab

Scand J Rheumatol. 2011 Mar;40(2):150-2. doi: 10.3109/03009742.2010.499878. Epub 2010 Sep 26.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antirheumatic Agents / adverse effects
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Juvenile / complications
  • Arthritis, Juvenile / drug therapy*
  • Arthritis, Juvenile / immunology
  • Child
  • Etanercept
  • Female
  • Finland
  • HLA-B27 Antigen / blood
  • Humans
  • Immunoglobulin G / adverse effects
  • Immunoglobulin G / therapeutic use*
  • Incidence
  • Inflammatory Bowel Diseases / chemically induced
  • Inflammatory Bowel Diseases / epidemiology*
  • Inflammatory Bowel Diseases / etiology
  • Infliximab
  • Male
  • Receptors, Tumor Necrosis Factor / therapeutic use*
  • Retrospective Studies
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • HLA-B27 Antigen
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Etanercept